Health Condition 1: C629- Malignant neoplasm of testis, unspecified whether descended or undescended
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Intervention4: Nil: Nil
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Histologically or clinically (based on tumor marker diagnosis) proven TGCT. Patients 15 years of age and above, registered in TMH + ACTREC. Patients with testicular germ cell tumor who have undergone RPLND.
Exclusion criteria
Exclusion criteria: Patients who have undergone RPLND for non-germ cell tumors. Patients who have not had the first 3 monthly follow up with Tata Memorial Hospital and ACTREC.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the Overall Survival (OS) of patients who have undergone RPLND for TGCT at Tata Memorial Centre.Timepoint: Date of treatment (RPLND) to death (due to any cause) or last follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease Free Survival (DFS) Cancer Specific Survival (CSS) 30-day Perioperative Complications (Clavien-Dindo) Incidence of scrotal violation and surgery for undescended testis Need for salvage or desperation RPLND Indications and surgical outcome of redo RPLND Outcome of patients with extra retroperitoneal disease Histopathological concordance (RPLND vs Orchiectomy / Extra-RPLND) Utility of serum tumor markers (AFP, BHCG, LDH) during surveillance Outcome of antegrade ejaculation (nerve-sparing RPLND) Operative time, blood loss, and length of hospital stay Comparison of robotic vs open RPLND outcomesTimepoint: Assessed during perioperative period (up to 30 days post-surgery) and during follow-up up to last follow-up (prospective cohort followed for minimum 2 years post-RPLND). | — |
Countries
India
Contacts
Public ContactDr Gagan Prakash
Tata Memorial Hospital,Parel
Outcome results
None listed